Omjjara Dosage/Direction for Use

Treatment should be initiated and monitored by physicians experienced in the use of anti-cancer medicinal products.
Posology: Omjjara should not be used in combination with other JAK inhibitors.
The recommended dose is 200 mg once daily.
Complete blood cell count and liver function tests must be performed before initiating treatment, periodically during treatment, and as clinically indicated (see Precautions).
Dose modifications: Dose modifications should be considered for haematologic and non-haematologic toxicities (see Table 3).

Click on icon to see table/diagram/image

Treatment with Omjjara should be discontinued in patients unable to tolerate 100 mg once daily.
Duration of use: Treatment may be continued for as long as the benefit-risk remains positive for patients, as assessed by the treating physician.
Missed dose: If a dose of Omjjara is missed, the next scheduled dose should be taken the following day. Two doses should not be taken at the same time to make up for the missed dose.
Special populations: Elderly: No dose adjustment is required for patients who are aged 65 years and older (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: No dose adjustment is required for patients with renal impairment (>15 mL/min).
Omjjara has not been studied in patients with end-stage renal disease.
Hepatic impairment: No dose adjustment is recommended for patients with mild or moderate hepatic impairment (see Precautions). The recommended starting dose of Omjjara is 150 mg once daily in patients with severe hepatic impairment (Child-Pugh Class C) (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of Omjjara in children and adolescents less than 18 years of age have not been established. No data are available.
Method of administration: Omjjara is for oral use only and can be taken with or without meals (see Pharmacology: Pharmacokinetics under Actions).